Publications
Here you can review available Corcept-sponsored publications.
Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Corcept does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Access Corcept-sponsored publications below.
Filter by:
2026
Relacorilant
Efficacy and Safety of Relacorilant for the Treatment of Patients With Cushing’s Syndrome (GRACE): A Multicentre, Phase 3, Double-Blind, Placebo-Controlled, Randomised-Withdrawal Study
Pivonello R, Arnaldi G, Auchus RJ
2026
Investigating Endogenous Hypercortisolism Prevalence in a US Population with Resistant Hypertension: MOMENTUM Rationale and Design
Plutzky J, Taub PR, Bhatt DL, et al.
2026
Relacorilant
Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer
Flint MS, O’Malley DM, Lorusso D, et al.
2026
Relacorilant
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
Lorusso D, Gladieff L, O’Malley DM, et al.
2025
Relacorilant
Relacorilant or surgery improved hemostatic markers in Cushing syndrome
Simeoli C, Di Paola N, Stigliano A, et al
2025
Mifepristone
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment
DeFronzo RA, Fonseca V, Aroda VR, et al
2025
Mifepristone
Identification of Endogenous Hypercortisolism and the Effect of Mifepristone Treatment in Patients With Difficult-to-Manage Diabetes: A Case Series
Lucci CP, McCoy G
2025
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Buse JB, Kahn SE, Aroda VR, et al.
2025
Relacorilant
Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)
Shahin MS, Mathur R, Parthan A, et al.
2025
Relacorilant
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
Olawaiye AB, Gladieff L, O'Malley DM, et al.
2024
Relacorilant
Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval
Donegan DM, Pivonello R, Stigliano A, et al
2024
Mifepristone
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone
DeFronzo RA, Auchus RJ, Bancos I, et al
2023
Relacorilant
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
Colombo N, Van Gorp T, Matulonis UA, et al.
2023
Relacorilant
The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol
Greenstein AE, Hunt HJ
2023
Relacorilant
Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators
Mallick S, Chakrabarti J, Eschbacher J, et al.
2022
Relacorilant
Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
Pivonello R, Bancos I, Feelders RA, et al
2022
Relacorilant
Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition
Viho EMG, Kroon J, Feelders RA, et al
2022
Relacorilant
Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant
Pivonello R, Munster PN, Terzolo M, et al.
2022
Relacorilant
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Munster PN, Greenstein AE, Fleming GF, et al.
2021
When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis
Aresta A, Soranna D, Giovanelli L, et al
2021
Hidden hypercortisolism: a too frequently neglected clinical condition
Giovanelli L, Aresta C, Favero V, et al.
2021
Relacorilant
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
Pivonello R, Bancos I, Feelders RA, et al
2021
Mifepristone
Mifepristone as Bridge or Adjunct Therapy in the Management of Challenging Cushing Disease Cases
Chang AY, Mirfakhraee S, King EE, et al.
2021
Relacorilant
Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells
Greenstein AE, Hunt HJ
2021
Relacorilant
Adrenal tumors provide insight into the role of cortisol in NK cell activity
Greenstein AE, Habra MA, Wadekar SA, et al.
2020
Mifepristone
Clinical Management of patients with Cushing Syndrome treated with mifepristone: consensus recommendations
Brown DR, East HE, Eilerman BS, et al.
2019
Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients
Steffensen C, Dekkers OM, Lyhne J, et al
2018
Relacorilant
Assessment of Safety,Tolerability,Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Study
Hunt H, Donaldson K, Strem M, et al.
2017
Mifepristone
Evaluation of evidence of adrenal insufficiency in trials of normocortisolemic patients treated with mifepristone
Yuen KCJ, Moraitis A, Nguyen D
2017
Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth
Kach J, Long TM, Tonsing-Carter EY, et al.
2017
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay
Block TS, Murphy TI, Munster PN, et al.
2017
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer
Veneris JT, Darcy KM, Mhawech-Fauceglia P, et al.
2016
Mifepristone
Mifepristone improves octreotide efficacy in resistant ectopic Cushing’s syndrome
Moraitis AG, Auchus RJ
2016
Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis
Steffensen C, Pereira AM, Dekkers OM, Jørgensen JOL
2016
Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study
Costa DS, Conceição FL, Leite NC, Ferreira MT, Salles GF, Cardoso CRL
2016
Mifepristone
A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer
Nanda R, Stringer-Reasor EM, Saha P, et al.
2015
Mifepristone
Association between mifepristone dose, efficacy, and tolerability in patients with Cushing syndrome
Yuen KCJ, Williams G, Kushner H, Nguyen D
2015
Mifepristone
Mifepristone and Cushing syndrome: A commentary
Kennedy L
2015
Mifepristone
Persistent Weight Loss in Patients Treated With Mifepristone for Cushing's Syndrome: Results From the SEISMIC & Long-Term Extension Studies
Fein HG, Vaughan III B, Gross C, et al.
2015
Relacorilant
Mifepristone
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma
Stringer-Reasor EM, Baker GM, Skor MN, et al.
2015
Mifepristone
Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer
Baker GM, Murphy TI, Block TS, et al.
2014
Long-Term Follow-Up in Adrenal Incidentalomas: An Italian Multicenter Study
Morelli V, Reimondo G, Giordano R, et al.
2014
Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study
Di Dalmazi G, Vicennati V, Garelli S, et al.
2014
Cortisol as a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas
Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J
2014
Mifepristone
Global clinical response in Cushing’s syndrome patients treated with mifepristone
Katznelson L, Loriaux DL, Feldman D, et al.
2014
Mifepristone
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer
Isikbay M, Otto K, Kregel S, et al.
2014
Steroid receptors aplenty in prostate cancer
Sharifi N
2013
Mifepristone
A new therapeutic approach in the medical treatment of Cushing’s syndrome: glucocorticoid receptor blockade with mifepristone
Fleseriu M, Molitch ME, Gross C, Schteingart DE, Vaughan TB, Biller BMK
2013
Mifepristone
Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects.
Wallia A, Colleran K, Purnell JQ, et al.
2013
Mifepristone
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer
Skor MN, Wonder EL, Kocherginsky M, et al.
2012
Mifepristone
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome
Fleseriu M, Biller BMK, Findling JW, et al.
2012
Mifepristone
Mifepristone inhibits GRβ coupled prostate cancer proliferation
Ligr M, Li Y, Logan SK, et al.
2011
“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers
Nanda R
2011
Mifepristone
Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression
Tiezen CR, Goyeneche AA, Brandhagen BN, et al.
2009
Administration of Glucocorticoids to Ovarian Cancer Patients Is Associated with Expression of the Anti-apoptotic Genes SGK1 and MKP1/DUSP1 in Ovarian Tissues
Melhem A, Yamada SD, Fleming GF, et al.
2008
Minireview: nuclear receptors and breast cancer
Conzen SD
2008
Mifepristone
Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer
Yan TZ, Jin FS, Xie LP, et al.
2008
Mifepristone
Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro
Zhang H, Lü J, Gao Q, et al.
2001
Mifepristone
Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486)
Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D
1999
The biology of hormone refractory prostate cancer. Why does it develop?
Isaacs JT.